REFERENCES
1. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 2015;17:351-9.
2. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 2019;121:725-37.
3. Escrivá-de-Romaní S, Arumí M, Bellet M, Saura C. HER2-positive breast cancer: current and new therapeutic strategies. Breast 2018;39:80-8.
4. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005;5:172-83.
5. O'Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
6. Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol 2021;14:2.
7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
8. Howlander N, Noone A, Krapcho M, et al. Survival rates for gastrointestinal stromal tumors. Available from: https://www.cancer.org/cancer/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html [Last accessed on 17 Dec 2021].
9. Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the 'undruggable' cancer targets. Nat Rev Cancer 2017;17:502-8.
10. Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel) 2014;6:1769-92.
11. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017;18:1493-501.
12. Keung EZ, Burgess M, Salazar R, et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. Clin Cancer Res 2020;26:1258-66.
13. Dancsok AR, Asleh-Aburaya K, Nielsen TO. Advances in sarcoma diagnostics and treatment. Oncotarget 2017;8:7068-93.
14. D'angelo SP, Tap WD, Schwartz GK, Carvajal RD. Sarcoma immunotherapy: past approaches and future directions. Sarcoma 2014;2014:391967.
16. Hall F, Villalobos V, Wilky B. Future directions in soft tissue sarcoma treatment. Curr Probl Cancer 2019;43:300-7.
17. Bourcier K, Le Cesne A, Tselikas L, et al. Basic knowledge in soft tissue sarcoma. Cardiovasc Intervent Radiol 2019;42:1255-61.
19. Tsukamoto S, Errani C, Angelini A, Mavrogenis AF. Current treatment considerations for osteosarcoma metastatic at presentation. Orthopedics 2020;43:e345-58.
20. Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr 2016;28:26-33.
21. Yen CC, Chen TW. Next frontiers in systemic therapy for soft tissue sarcoma. Chin Clin Oncol 2018;7:43.
22. Nebbioso A, Tambaro FP, Dell'Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet 2018;14:e1007362.
24. Kanwal R, Gupta K, Gupta S. . Cancer epigenetics: an introduction. In: Verma M, editor. Cancer epigenetics. New York: Springer; 2015. p. 3-25.
25. Asano T. Drug resistance in cancer therapy and the role of epigenetics. J Nippon Med Sch 2020;87:244-51.
26. Perez-Plasencia C, Duenas-Gonzalez A. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer 2006;5:27.
27. Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun 2021;12:1786.
28. Zhang YW, Zheng Y, Wang JZ, et al. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. Epigenetics 2014;9:896-909.
29. Soini Y. Epigenetic and genetic changes in soft tissue sarcomas: a review. APMIS 2016;124:925-34.
30. Cote GM, Choy E. Role of epigenetic modulation for the treatment of sarcoma. Curr Treat Options Oncol 2013;14:454-64.
31. Cancer Genome Atlas Research Network. Electronic address: [email protected], Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 2017;171:950-65.e28.
32. Bui NQ, Przybyl J, Trabucco SE, et al. A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis. Clin Sarcoma Res 2019;9:12.
33. Koelsche C, Schrimpf D, Stichel D, et al. Sarcoma classification by DNA methylation profiling. Nat Commun 2021;12:498.
34. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35.
35. Kimura H, Nakamura T, Ogawa T, Tanaka S, Shiota K. Transcription of mouse DNA methyltransferase 1 (Dnmt1) is regulated by both E2F-Rb-HDAC-dependent and -independent pathways. Nucleic Acids Res 2003;31:3101-13.
36. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013;31:2024-8.
37. Dickson MA, Schwartz GK, Keohan ML, et al. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor Palbociclib: a phase 2 clinical trial. JAMA Oncol 2016;2:937-40.
38. Roncati L, Barbolini G, Sartori G, Siopis E, Pusiol T, Maiorana A. Loss of CDKN2A promoter methylation coincides with the epigenetic transdifferentiation of uterine myosarcomatous cells. Int J Gynecol Pathol 2016;35:309-15.
39. Stewart E, McEvoy J, Wang H, et al. St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Identification of therapeutic targets in rhabdomyosarcoma through integrated genomic, epigenomic, and proteomic analyses. Cancer Cell 2018;34:411-26.e19.
40. Ciarapica R, Carcarino E, Adesso L, et al. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. BMC Cancer 2014;14:139.
41. Marchesi I, Sanna L, Fais M, Fiorentino FP, Giordano A, Bagella L. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: a novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells. J Cell Physiol 2018;233:2360-5.
42. Zoroddu S, Marchesi I, Bagella L. PRC2: an epigenetic multiprotein complex with a key role in the development of rhabdomyosarcoma carcinogenesis. Clin Epigenetics 2021;13:156.
43. Hale R, Sandakly S, Shipley J, Walters Z. Epigenetic targets in synovial sarcoma: a mini-review. Front Oncol 2019;9:1078.
44. Chu QS, Nielsen TO, Alcindor T, et al. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†. Ann Oncol 2015;26:973-81.
45. Tang F, Choy E, Tu C, Hornicek F, Duan Z. Therapeutic applications of histone deacetylase inhibitors in sarcoma. Cancer Treat Rev 2017;59:33-45.
46. Li Y, Geng P, Jiang W, et al. Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells. Tumour Biol 2014;35:4831-9.
47. Xie A, Odate S, Chandramouly G, Scully R. H2AX post-translational modifications in the ionizing radiation response and homologous recombination. Cell Cycle 2010;9:3602-10.
49. Nacev BA, Jones KB, Intlekofer AM, et al. The epigenomics of sarcoma. Nat Rev Cancer 2020;20:608-23.
50. Sakimura R, Tanaka K, Nakatani F, et al. Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int J Cancer 2005;116:784-92.
51. Santos MP, de Farias CB, Roesler R, Brunetto AL, Abujamra AL. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncol Rep 2014;31:955-68.
52. Ma Y, Baltezor M, Rajewski L, et al. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. J Mol Med (Berl) 2019;97:957-72.
53. Choi JH, Ro JY. The 2020 WHO classification of tumors of soft tissue: selected changes and new entities. Adv Anat Pathol 2021;28:44-58.
54. Gatta G, van der Zwan JM, Casali PG, et al. RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011;47:2493-511.
55. Ray-Coquard I, Montesco MC, Coindre JM, et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 2012;23:2442-9.
56. Italiano A, Di Mauro I, Rapp J, et al. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study. Lancet Oncol 2016;17:532-8.
57. Zhang P, Pollock RE. Epigenetic regulators: new therapeutic targets for soft tissue sarcoma. Cancer Cell Microenviron 2014;1:e191.
58. Cooper S, Dienstbier M, Hassan R, et al. Targeting polycomb to pericentric heterochromatin in embryonic stem cells reveals a role for H2AK119u1 in PRC2 recruitment. Cell Rep 2014;7:1456-70.
59. McDermott M, Eustace AJ, Busschots S, et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Front Oncol 2014;4:40.
60. Zakharia Y, Monga V, Swami U, et al. Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: a phase lb study. Oncotarget 2017;8:89182-93.
62. Italiano A. Targeting epigenetics in sarcomas through EZH2 inhibition. J Hematol Oncol 2020;13:33.
63. Dembla V, Groisberg R, Hess K, et al. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep 2017;7:15963.
64. van der Graaf WT, Blay J, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.
65. Monga V, Swami U, Tanas M, et al. A phase I/II study targeting angiogenesis using bevacizumab combined with chemotherapy and a histone deacetylase inhibitor (Valproic Acid) in advanced sarcomas. Cancers (Basel) 2018;10:53.
66. Verschraegen CF, Arias-Pulido H, Lee SJ, et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol 2012;23:785-90.
67. Agulnik M, Yarber JL, Okuno SH, et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 2013;24:257-63.
68. Monga V, Dodd R, Scherer A, et al. Phase Ib study of decitabine in combination with gemcitabine in treatment of advanced soft tissue and bone sarcomas. J Clin Oncol 2020;38:11550.
69. Bauman J, Shaheen M, Verschraegen CF, et al. A phase I protocol of hydralazine and valproic acid in advanced, previously treated solid cancers. Transl Oncol 2014;7:349-54.
70. Murata K, Hamada M, Sugimoto K, Nakano T. A novel mechanism for drug-induced liver failure: inhibition of histone acetylation by hydralazine derivatives. J Hepatol 2007;46:322-9.
71. Campos Vidal B, Mello MLS. Sodium valproate (VPA) interactions with DNA and histones. Int J Biol Macromol 2020;163:219-31.
72. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006;6:2.
